Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%
MT Newswires Live
Mar 09
Amplia Therapeutics (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.
Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.
The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.
Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.
Amplia Therapeutics' shares fell 9% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.